Form 4: Turn Therapeutics CFO Awarded 240,000 Stock Options

Turn Therapeutics' Interim CFO, Zuraiz Chaudhary, was granted 240,000 employee stock options under the company's 2025 Omnibus Incentive Plan.

Summary

• Zuraiz Chaudhary, Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer of Turn Therapeutics Inc. (TTRX), was awarded 240,000 employee stock options.
• The options were granted on October 8, 2025, under the Company's 2025 Omnibus Incentive Plan.
• Each option has an exercise price of $10 and allows the holder to buy one share of common stock.
• The options will vest over time, with 25% vesting on May 1, 2026, and the remaining 75% vesting in equal quarterly installments of 6.25% thereafter.
• Vesting is contingent upon Zuraiz Chaudhary's continued employment with the company.
• The options have an expiration date of October 7, 2035.

Sentiment

Score: 6

Explanation: The filing reflects a routine executive compensation event, which is generally positive for aligning management incentives but does not introduce new fundamental information to significantly alter the company's outlook.

Positives

• The grant of stock options aligns the financial interests of the Interim CFO with those of the shareholders, incentivizing long-term performance and value creation.
• The options are granted under an established 2025 Omnibus Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• The exercise of these options in the future could lead to a dilution of existing shareholder equity, although this is a standard aspect of stock-based compensation.

Risks

• The options' value is dependent on the future market price of Turn Therapeutics Inc. common stock exceeding the $10 exercise price.
• Vesting of the options is subject to Zuraiz Chaudhary's continued employment, posing a risk to the individual if employment ceases before full vesting.

Future Outlook

The grant of stock options provides a long-term incentive for the Interim CFO, suggesting an expectation of continued employment and contributions to the company's future performance and shareholder value over the next decade.

Industry Context

The granting of stock options to key executives is a common practice across various industries, particularly in the biotechnology and pharmaceutical sectors, to attract, retain, and motivate talent by linking their compensation to the company's long-term stock performance.

Comparison to Industry Standards

• The use of stock options as a component of executive compensation is a standard practice within the industry, aligning executive incentives with shareholder interests.
• The specific size of the grant (240,000 options) and the exercise price ($10) would typically be benchmarked against peer companies of similar size and stage of development, though no specific comparable companies or projects are mentioned in this filing.

Management Changes

Corporate Governance

Related Party Transactions

• Grant of 240,000 employee stock options to Zuraiz Chaudhary, an officer of Turn Therapeutics Inc., as part of his compensation package under the company's 2025 Omnibus Incentive Plan.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through incentivized management, balanced against potential future dilution from option exercise.
• Employees (specifically Zuraiz Chaudhary): Significant long-term incentive tied to company performance and continued employment.

Next Steps

• The options will begin to vest on May 1, 2026, and continue quarterly thereafter, subject to the reporting person's continued employment.
• Zuraiz Chaudhary may choose to exercise these options at any time after vesting and before the expiration date of October 7, 2035, provided the stock price is favorable.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant and does not contain new fundamental information that would warrant a change in investment recommendation. The grant aligns management incentives with shareholder interests, which is generally positive, but it is an expected event for a publicly traded company.

Keywords

Turn Therapeutics, TTRX, stock options, executive compensation, Zuraiz Chaudhary, CFO, Form 4, insider transaction, equity incentive plan